7 Best Peptides for Sexual Health

What to Know Before Choosing a Peptide for Sexual Health

Sexual health is one of the more complex areas in the peptide landscape because the goal itself is not one thing. Low desire, erectile difficulty, difficulty with arousal or orgasm, and hormone-driven decline each involve different biology, and different compounds map onto different parts of that picture. The list below covers the peptides people are actually using or discussing for sexual health goals in 2026, including FDA-approved options, compounds available through telemedicine and functional medicine clinics, and research-only compounds whose use is largely community-reported. Evidence strength varies considerably across the list, and that variation is stated honestly inside each entry rather than used as a filter for who makes the cut.

A compound earns a slot here because people use it or are actively discussing it for sexual health, not because it has passed a particular regulatory bar or accumulated a certain number of randomized trials. FDA-approved, telemedicine-prescribed, and research-only compounds are all represented. Where the evidence is thin or absent in human studies, that is stated plainly so the reader can weigh it accurately.

The entries are numbered because the title promises a count, and the numbers give the list a spine. They reflect how prominently each compound appears in research and real-world use for sexual health, not a ranking of which compound is better for any individual. The right compound depends on the specific goal, health history, and what a clinician or the app helps build into a plan.

1. Bremelanotide (PT-141): For Central Desire and Arousal

Bremelanotide, sold under the brand name Vyleesi, is the only peptide with FDA approval for a sexual health indication. It was approved in 2019 for hypoactive sexual desire disorder in premenopausal women, a condition characterized by persistently low sexual desire that causes personal distress. Its use in men for erectile dysfunction and low libido is off-label but widespread, supported by Phase I and Phase II trial data and substantial real-world use through functional medicine clinics and telemedicine platforms.

What sets bremelanotide apart from most treatments for sexual function is where it acts. Rather than targeting blood flow peripherally the way PDE5 inhibitors like sildenafil do, bremelanotide works in the brain. It binds to melanocortin receptors called MC4R and MC3R, the brain receptors that govern desire and motivation, located in the hypothalamus. That binding triggers dopamine release in several areas associated with reward and arousal, including the nucleus accumbens and the medial preoptic area. A secondary effect is a local increase in nitric oxide in penile tissue, which relaxes smooth muscle and supports physical response. The result is a compound that works upstream of the blood flow problem, addressing desire at the neurological level rather than facilitating erection mechanically.

The clinical evidence for women with hypoactive sexual desire disorder is the strongest of any peptide in this category. Phase III trials showed statistically significant improvements in desire, reductions in sexual distress, and increased numbers of satisfying sexual events, measured on validated scales including the Female Sexual Function Index. For men, Phase I and Phase II data showed bremelanotide induced erections in men who were non-responsive to sildenafil. A Phase IIb trial in men with diabetes-related erectile dysfunction showed meaningful improvements over three months on the International Index of Erectile Function. That evidence is promising but was not sufficient for regulatory approval in men, so use in men remains off-label.

Community reports add context the trials do not fully capture. Users consistently describe a longer onset than the approximate 45-minute pre-activity window in the prescribing guidance. Effects are commonly reported as taking five to eight hours to develop, which requires planning ahead. Nausea is the most frequently mentioned side effect, affecting roughly 40 percent of users in clinical data. Flushing, headache, and injection site reactions also appear regularly. Bremelanotide causes a transient increase in blood pressure, typically peaking around four hours after administration and returning to baseline by eight to ten hours, so it is contraindicated for people with uncontrolled hypertension or cardiovascular disease.

One regulatory matter is relevant in 2026: the FDA listed compounded bremelanotide as unsafe for compounding as of 2023, and the agency's bulk drug substances list has carried a pending review of that designation with a possible change expected around mid-2026. The approved formulation is Vyleesi, the subcutaneous auto-injector pen available by prescription. Compounded versions circulating through telemedicine channels are not the same product, and quality and dosing consistency in that channel vary.

2. Kisspeptin: For Hormonal Drive and Reproductive Axis Support

Kisspeptin is an endogenous neuropeptide, meaning the body produces it naturally, and it plays a central role in the signaling chain that controls sex hormone production. It acts on neurons in the hypothalamus that release gonadotropin-releasing hormone, a chemical signal that tells the pituitary gland to start producing sex hormones. That signal prompts the pituitary to secrete luteinizing hormone, a pituitary signal that tells the testes to make testosterone, and follicle-stimulating hormone, which supports sperm and egg development. Those hormones drive testosterone production in men and support reproductive signaling in both sexes. The practical interest in kisspeptin for sexual health comes from this hormonal pathway: when the system is running well, testosterone levels tend to be adequate, and sexual desire tends to follow.

Human trials have been conducted for kisspeptin in men with low sexual desire, and early results showed it modulated sexual brain activity and increased reported desire. That evidence is not as deep or as large as the bremelanotide trial record, and kisspeptin is not FDA-approved for any sexual health indication, but human data does exist and shows a measurable neurological effect. In clinical and wellness settings it is typically delivered as a nasal spray or as a troche, a small tablet that dissolves under the tongue, both of which allow rapid access to the circulation without injection.

In community use, kisspeptin is often stacked with bremelanotide in protocols targeting libido and hormone regulation together, and with growth hormone secretagogues in protocols focused on broader hormonal optimization. Users in those contexts report heightened motivation and emotional engagement alongside the hormonal effects, though those reports are anecdotal. The honest picture is a compound with a plausible and well-characterized mechanism, early human trial data showing neurological activity relevant to desire, and a meaningful community of users running it for hormone-driven sexual health goals.

3. Melanotan II: For Libido and Erection via Melanocortin Activation

Melanotan II is a synthetic analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide. It is a predecessor to bremelanotide on the melanocortin pathway: both bind to MC3R and MC4R receptors, but melanotan II is a broader and less selective compound with a heavier side effect profile, which is part of why research into it led to the development of the more refined bremelanotide. Melanotan II is not FDA-approved and is not available through licensed telemedicine channels in the US for sexual health purposes. It circulates primarily through research chemical markets.

The sexual effects of melanotan II were initially described as side effects in tanning research rather than as the primary purpose of study. Placebo-controlled trials in men with psychogenic erectile dysfunction showed it induced erections and increased sexual desire and penile rigidity in a meaningful proportion of participants. Those trials represent real published evidence for a genuine pharmacological effect on sexual function, not purely anecdotal reporting. At the same time, the evidence base is modest in size, the compound carries risks the approved bremelanotide does not, including unintended and sometimes persistent skin pigmentation changes, and its unknown long-term risk profile reflects its status as an unapproved compound.

Community users describe firmer erections and significantly increased libido, with some reporting effects they found comparable to or exceeding PDE5 inhibitors. That reporting is consistent across multiple independent sources, which gives it more weight than isolated accounts, though it is not controlled data. Sourcing and purity risk from the research chemical market is a genuine consideration for anyone approaching this compound. The sexual effects are pharmacologically real; the risk profile is less well-characterized than bremelanotide's, and access carries more uncertainty.

4. Oxytocin: For Arousal, Bonding, and the Psychological Dimension

Oxytocin is a neuropeptide hormone produced in the hypothalamus, most widely recognized for its role in bonding, trust, and emotional connection. Its relevance to sexual health comes from a different angle than desire or erection: it modulates the dopaminergic and serotonergic circuits in the limbic system. The dopaminergic and serotonergic circuits are the brain's reward and mood signaling networks, and the limbic system is the region that governs emotional response and motivation. Oxytocin's activity in these areas enhances arousal and intimacy. It also enhances parasympathetic nervous system tone, the part of the nervous system associated with relaxation and receptive states, and appears to facilitate orgasm intensity and lubrication. It is particularly discussed in the context of sexual health issues with a significant psychological or relational component.

Oxytocin is not FDA-approved for sexual health use, and the clinical trial record for sexual dysfunction specifically is not deep. Studies in both men and women have shown it can enhance aspects of arousal and orgasmic function, but large randomized controlled trials, the gold-standard controlled studies that establish a therapy for a defined condition, have not been completed for sexual dysfunction specifically. It is used in clinical settings, typically as a nasal spray to allow rapid brain access, either alone or in combination protocols, particularly in female sexual health programs.

The evidence for oxytocin in this context is a combination of small human studies showing relevant effects, a well-understood mechanism, and off-label clinical use by practitioners working in sexual medicine and functional health. Users report improvements in intimacy, emotional connection during sex, and orgasm intensity, but those reports are not controlled. The honest state of the evidence is a compound with a plausible mechanism and early signals in human research, not one with a robust clinical trial package behind it.

5. Sermorelin: For Sexual Health via Growth Hormone Optimization

Sermorelin is a growth hormone-releasing hormone analogue, meaning it prompts the pituitary gland to release more of its own growth hormone rather than supplying growth hormone directly. Its connection to sexual health is indirect but mechanistically coherent: growth hormone supports the hormonal environment broadly, and adequate levels correlate with healthier testosterone and estrogen levels, better energy, improved mood, and reduced metabolic dysfunction, all of which contribute to sexual drive and function. Sermorelin appears on the sexual health compound lists of functional medicine clinics as a component of comprehensive hormonal programs.

Sermorelin is not FDA-approved specifically for sexual health, but it has a longer history in clinical medicine than most compounds in this category, having been used in growth hormone deficiency protocols for years. The evidence base is primarily from hormone optimization contexts rather than sexual dysfunction trials: it reliably stimulates growth hormone release, and the downstream hormonal effects are well-characterized. Whether those hormonal improvements translate to measurable sexual health outcomes in clinical trial terms has not been directly tested in large trials focused on sexual function.

In practice, sermorelin is often used as part of a broader hormonal optimization protocol rather than as a standalone sexual health compound. Clinics commonly pair it with compounds that target the desire-and-arousal pathway more directly, treating sermorelin as the hormonal foundation on which more targeted interventions can work more effectively. The evidence for that combined approach rests on clinical experience and mechanistic reasoning rather than controlled trials, but its use in this context is established enough that it belongs in any honest account of the field.

6. BPC-157: For Vascular Function and Sensation Restoration

BPC-157, short for Body Protection Compound-157, is a peptide derived from a protein found in gastric juice. It is primarily studied for tissue repair, inflammation reduction, and angiogenesis, the formation of new blood vessels. Its route into sexual health discussions is more specific: in preclinical rat models, BPC-157 upregulated nitric oxide signaling in penile tissue, specifically the endothelial nitric oxide synthase pathway, which is the enzyme system that produces nitric oxide in blood vessel walls, and the cyclic GMP cascade, a signaling chain that relaxes smooth muscle tissue. That relaxation occurs in the corpus cavernosum, the spongy tissue inside the penis that fills with blood during erection, and supports the physical erectile response. That mechanism is studied and plausible, though it has been demonstrated in animal models only and has not been tested in human sexual dysfunction trials.

The most discussed human context for BPC-157 in sexual health is post-SSRI sexual dysfunction, a condition in which sexual function does not recover after stopping selective serotonin reuptake inhibitor antidepressants. Community reports in this context are notable for their specificity. One account that recurs across multiple platforms describes a person with post-SSRI sexual dysfunction who reported permanent restoration of orgasmic sensation after ten days of use, with effects persisting for two years after stopping. That account is careful about what was and was not resolved: sensation and orgasm intensity improved substantially, but physical engorgement did not. That distinction makes mechanistic sense, given that BPC-157's studied effect is on the nitric oxide pathway and smooth muscle rather than on central desire circuitry.

No human clinical trial data has been published for BPC-157 in sexual dysfunction as of 2026. What exists is preclinical animal data showing a plausible mechanism and community-reported experience, some of it quite specific and consistent. BPC-157 is a research-only compound in the US, not FDA-approved, not available through licensed telemedicine for sexual health, and sourced through research chemical markets. The mechanism is biologically grounded, the human evidence is absent in clinical trial terms, and the community reports are specific enough to be worth naming plainly.

7. Semax: For Dopaminergic Drive and Sexual Motivation

Semax is a synthetic neuropeptide originally developed in Russia and registered there as a medication, primarily for cognitive and neurological applications. Its mechanism relevant to sexual health is dopaminergic: it enhances dopamine transmission in reward-related brain circuits, which overlap significantly with the circuits governing sexual motivation. In rodent models, semax increased partner exploration time by roughly 28 to 34 percent compared to controls, a behavioral measure of sexual motivation. That evidence is preclinical only, and no human clinical trial data exists for semax in sexual health as of 2026.

Community interest in semax for sexual health tends to come from people looking for adjuncts that work on motivation and drive rather than physical arousal or hormonal levels. Users report a subjective increase in motivation broadly, which some describe as extending to sexual interest, though separating a general motivational effect from a specific sexual one is not possible without controlled data. Semax is a research-only compound in the US and not FDA-approved. Its registered status in Russia does not affect its regulatory standing in other jurisdictions.

The honest picture for semax in sexual health: the mechanism is biologically plausible, the animal data is consistent with an effect on sexual motivation, and people are using it in this context. Human trial data for this specific application is absent. Anyone incorporating semax into a sexual health protocol is working from animal study extrapolation and community reports rather than from clinical evidence.

How These Peptides Compare

Frequently Asked Questions

Is bremelanotide the only peptide that is legal to use for sexual health in the US?

Bremelanotide marketed as Vyleesi is the only FDA-approved peptide for a sexual health indication, specifically hypoactive sexual desire disorder in premenopausal women. Several other peptides on this list, including sermorelin and kisspeptin, can be prescribed off-label by licensed practitioners and dispensed through compounding pharmacies, which is lawful under US prescribing rules even without an FDA-approved sexual health indication. Research-only compounds like BPC-157, semax, and melanotan II are not approved for human use and are sold strictly as research chemicals, placing them in a different regulatory category entirely.

How is peptide-based sexual health different from taking something like Viagra?

Most PDE5 inhibitors like sildenafil work on vascular smooth muscle, increasing blood flow to the genitals by preventing the breakdown of a signaling molecule that relaxes those blood vessels. The mechanism is peripheral and physical. Most peptides discussed for sexual health work earlier in the chain: either in the brain on desire and motivation circuits, on the hormonal axis that regulates testosterone and reproductive signaling, or on the nitric oxide pathway at the tissue level. The practical implication is that some people who do not respond to PDE5 inhibitors do respond to bremelanotide, because the underlying issue was neurological signaling or desire rather than blood flow.

How long do effects from these peptides typically last?

This varies substantially by compound. Bremelanotide's onset is commonly reported to take several hours, with user accounts placing it between five and eight hours after administration, and effects are often described as lasting up to 48 hours. Oxytocin delivered as a nasal spray acts more quickly due to its direct route to the brain, with a shorter duration. Kisspeptin and sermorelin work on hormonal axes that operate over longer timeframes, so their effects develop over days to weeks of consistent use rather than within a single-use window. Which compound someone is using and which aspect of function it targets determines the timeline entirely.

Do any of these peptides work differently for women than for men?

Yes, and this matters for how the research should be read. Bremelanotide's strongest clinical trial data is in women with hypoactive sexual desire disorder, and its FDA approval is limited to premenopausal women. The Phase I and Phase II data for men is promising but represents a smaller and earlier-stage evidence base. Oxytocin and kisspeptin have been studied in both sexes and their mechanisms are relevant across the board, though trial populations and outcomes differ. Sermorelin and other growth hormone secretagogues affect testosterone differently in men and women given the different baseline hormonal environments. The compounds themselves act on pathways present in both sexes, but the evidence is uneven, and reading trial data carefully for which population was studied matters.

Are there safety concerns specific to using these compounds together?

Combining peptides is common in functional medicine and community protocols, but clinical evidence for combined use is limited and interactions are not well-studied. Stacking bremelanotide with compounds that also affect blood pressure or cardiovascular tone requires attention to the transient blood pressure increase bremelanotide causes. Combining hormonal compounds like sermorelin, kisspeptin, and growth hormone secretagogues affects multiple axes of hormone regulation simultaneously, which is best managed with practitioner oversight. The interactions of most proposed stacks remain untested in controlled settings, and the limited combined-use evidence available makes practitioner supervision especially important when running more than one compound at a time.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for sexual health in one place.